EC
ZBIO

EcoR1 Capital’s Zenas BioPharma ZBIO Stock Holding History

EcoR1 Capital’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20M Hold
789,500
– – 0.97% 17
2026
Q1 		$15.4M Hold
789,500
– – 0.66% 18
2025
Q4 		$28.7M Buy
+789,500
New +$26M 1.3% 15

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

EcoR1 Capital's ZBIO Position: Q2 2026 in Review

EcoR1 Capital held its Zenas BioPharma (ZBIO) position steady in Q2 2026 at 789,500 shares worth $20M. The position accounts for 0.97% of the portfolio, ranked #17.

EcoR1 Capital first reported a position in ZBIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $28.7M in Q4 2025. 145 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • EcoR1 Capital held 789,500 shares of Zenas BioPharma worth $20M as of Q2 2026.
  • EcoR1 Capital left its Zenas BioPharma share count unchanged in Q2 2026.
  • Zenas BioPharma made up 0.97% of EcoR1 Capital's portfolio in Q2 2026, its #17 holding.
  • EcoR1 Capital first reported a position in Zenas BioPharma in Q4 2025 and has held it in 3 quarters since.
  • EcoR1 Capital's Zenas BioPharma position peaked at $28.7M in Q4 2025.
  • 145 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on EcoR1 Capital's 13F filing for Q2 2026, filed 14 Aug 2026.